Prior studies have also identified a serine/glycine NME1 mutation (S120G) in 21% of a small cohort of advanced neuroblastoma tumors, but not in any low-stage tumors [49], and mutant NME1S120G was shown to abrogate the inhibitory effect of exogenously expressed NME1 on breast carcinoma cell motility [50]. Here, NME1 is linked to breast carcinoma.